Chen, Bin http://orcid.org/0000-0001-8858-874X
Garmire, Lana
Calvisi, Diego F.
Chua, Mei-Sze
Kelley, Robin K.
Chen, Xin http://orcid.org/0000-0002-9588-0164
Article History
Accepted: 6 November 2019
First Online: 3 January 2020
Change Date: 11 March 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41575-020-0288-6
Competing interests
: R.K.K. declares the following competing interests: research funding and/or supply of study drug to institution for conduct of clinical trials from Adaptimmune, Agios, AstraZeneca, Bayer, Bristol–Myers Squibb, Eli Lilly and Co, EMD Serono, Exelixis, Merck, Novartis, Partner Therapeutics, QED, Taiho; funding (to individual) for Independent Data Monitoring Committee membership by Genentech/Roche; Steering Committee/Advisory Board memberships (funding to institution) by Agios, AstraZeneca, Bristol–Myers Squibb; Steering Committee (without compensation): Exelixis. The other authors declare no competing interests.